2022
Analgesic effects of main indole alkaloid of kratom, mitragynine in acute pain animal model
Mat N, Bakar S, Murugaiyah V, Chawarski M, Hassan Z. Analgesic effects of main indole alkaloid of kratom, mitragynine in acute pain animal model. Behavioural Brain Research 2022, 439: 114251. PMID: 36503042, DOI: 10.1016/j.bbr.2022.114251.Peer-Reviewed Original ResearchConceptsAnti-inflammatory propertiesAnalgesic effectTRPV1 expressionAcute pain animal modelsEffective doseFemale Sprague-Dawley ratsPain animal modelsPain-like behaviorsNon-opioid receptorsOpioid receptor activationNumber of writhesSprague-Dawley ratsInflammatory painPain pathwaysTRPV1 receptorsDawley ratsWrithing behaviorED95 valuesRat brainAnimal modelsReceptor activationReceptor pathwayRatsBehavior scoresMain indole alkaloids
2020
Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study.
Vicknasingam B, Chooi WT, Rahim AA, Ramachandram D, Singh D, Ramanathan S, Yusof NSM, Zainal H, Murugaiyah V, Gueorguieva R, Mansor SM, Chawarski MC. Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study. The Yale Journal Of Biology And Medicine 2020, 93: 229-238. PMID: 32607084, PMCID: PMC7309661.Peer-Reviewed Original ResearchConceptsDouble-blind studyPain toleranceCold pressor taskConsumption of placeboSigns of withdrawalKratom consumptionTraditional medicine useKratom ingestionPain reliefPain onsetInpatient staySafety profileMedicine useWithdrawal symptomsPlacebo drinkHand withdrawalHealth statusVital signsKratom productsSelf-reported dataRandomized sequencePlaceboKratomSignificant increaseDecoction
2014
Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China
Zhang Y, Xu Z, Zhang S, Desrosiers A, Schottenfeld RS, Chawarski MC. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. Journal Of Psychiatric Research 2014, 53: 99-102. PMID: 24613031, PMCID: PMC4004368, DOI: 10.1016/j.jpsychires.2014.02.010.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePsychiatric symptomsAmphetamine-type stimulantsKetamine groupKetamine useAnxiety depressionInpatient psychiatry wardUrine toxicology screenProportion of participantsPsychiatric Rating ScaleLower scoresWard admissionToxicology screenClinical recordsPsychiatry wardInpatient treatmentHigher scoresPrimary drugATS useBPRS subscalesMajor drug problemStudy participantsKetamineSymptomsATS users